Abstract
Tyner and colleagues in the Center for Hematological Malignancies, Knight Cancer Institute, at the Oregon Health & Science University have recently developed a novel kinase-inhibitor assay and rapid mutation screening to identify molecularly targeted drugs to which patient leukemic cells are sensitive. As a proof of concept and feasibility trial, they proposed a phase IB trial focusing on feasibility and safety of an assay-based kinase-inhibitor treatment assignment in combination with the standard induction chemotherapy among newly diagnosed acute myeloid leukemia patients. Because each patient receives one of five kinase inhibitors in combination with standard chemotherapy, the sample size for each kinase inhibitor group is varied and limited. In addition, there is a different toxicity profile associated with each inhibitor, making safety assessment challenging. We will discuss a continuous toxicity monitoring plan in biomarker driven, multiple agent feasibility and safety trials, and evaluate its operating characteristics in a simulation study.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002;52(1):23–47. Erratum in: CA Cancer J Clin. 2002;52(2):119. CA Cancer J Clin. 2002;52(3):181–2. (PubMed PMID: 11814064).
Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Van der Lelie J, Boogaerts MA, Löwenberg B. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969–78 Epub 2005 Jan 4 (PubMed PMID: 15632409).
Giles F, O’Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104(3):547–54 (PubMed PMID: 15973664).
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;10(2):16010. doi:10.1038/nrdp.2016.10 (PubMed PMID: 27159408).
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–90. doi:10.1056/NEJMoa1214514 (PubMedPMID:23656643; PubMedCentralPMCID: PMC3730275).
Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005;61(2):540–5 (PubMed PMID: 16011702).
Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191–9.
Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton: Chapman & Hall/CRC; 2000.
Tang D, Gnecco C, Geller NL. Design of group sequential clinical trials with multiple endpoints. J Am Stat Assoc. 1989;84(407):776–9.
Ye Y, Li A, Liu L, Yao B. A group sequential Holm procedure with multiple primary endpoints. Stat Med 2012; Stat Med. 2013;32(7):1112–24. doi:10.1002/sim.5700. Epub 2012 Dec 14. PMID: 23239078.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Mori, M., Daffé, R., Park, B.S., Tyner, J. (2017). Evaluation of Safety in Biomarker Driven Multiple Agent Phase IB Trial. In: Matsui, S., Crowley, J. (eds) Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer, Singapore. https://doi.org/10.1007/978-981-10-0126-0_5
Download citation
DOI: https://doi.org/10.1007/978-981-10-0126-0_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-0124-6
Online ISBN: 978-981-10-0126-0
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)